Sernova Corp (TSE:SVA) has released an update.
Sernova Corp has announced the appointment of Dr. Bernd Muehlenweg from Evotec SE to its Board of Directors, as Dr. Daniel Mahony steps down. Dr. Muehlenweg’s extensive experience in the biotech and pharmaceutical industry, especially in business development and alliance management, is expected to reinforce Sernova’s strategic collaborations, particularly in advancing cell therapies for chronic diseases such as type 1 diabetes. The transition is anticipated to bolster Sernova’s commitment to enhancing patient lives and increasing shareholder value through its ongoing clinical trials and innovative treatments.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
